Gyre Therapeutics/$GYRE

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Gyre Therapeutics

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Ticker

$GYRE
Sector
Health
Primary listing
NASDAQ

Employees

579
Headquarters
San Diego, United States
Website
www.gyretx.com

GYRE Metrics

BasicAdvanced
$752M
487.72
$0.02
-
-

Bulls say / Bears say

Gyre’s lead candidate Hydronidone (F351) achieved statistically significant ≥1-stage liver fibrosis regression (52.85% vs 29.84%, P=0.0002) in its pivotal Phase 3 trial for CHB-associated fibrosis, supporting an NDA submission to China’s NMPA in Q3 2025 (GLOBE NEWSWIRE)
Gyre remains on track to commercially launch nintedanib in May 2025 for multiple fibrosing interstitial lung diseases—including IPF, SSc-ILD, and PF-ILD—expected to expand its pulmonary fibrosis treatment portfolio and drive second-half 2025 revenue growth (Nasdaq)
As of March 31, 2025, Gyre held a strong liquidity position with $51.3 million in cash, cash equivalents, and deposits, which management expects to fund operations for at least the next 12 months (Nasdaq)
Q1 2025 revenue declined 19% year-over-year to $22.1 million, primarily due to a $5.2 million drop in ETUARY® sales as Gyre shifted marketing resources to support upcoming product launches (SEC)
Revenues for the six months ended June 30, 2025 fell by $3.6 million to $48.8 million versus $52.4 million in H1 2024, driven by a $6.8 million decline in ETUARY® sales, partially offset by nascent Etorel and Contiva revenues (GlobeNewswire)
Net income for Q2 2025 was just $1.6 million, underscoring constrained profitability amid increased launch-related expenses (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.

GYRE News

AllArticlesVideos
Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker

Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker

Benzinga·3 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $GYRE

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs